Condition: Bladder Carcinoma · Ureter Carcinoma · Renal Pelvis Carcinoma · Sponsor: Guardant Health, Inc.
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
This description comes directly from the study's public registry record.
Clinical Trial Operations · 8556988887 · mrdoraclestudy@guardanthealth.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Ironwood Cancer & Research Centers | Chandler, Arizona, United States | Recruiting |
| Genesis Cancer Center | Hot Springs, Arkansas, United States | Terminated |
| University of California, San Diego | La Jolla, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Redwood City | Redwood City, California, United States | Recruiting |
| Sutter Institute for Medical Research | Sacramento, California, United States | Terminated |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Memorial Healthcare System | Hollywood, Florida, United States | Recruiting |
| The Oncology Institute of Hope & Innovation | Lakeland, Florida, United States | Recruiting |
| Tulane Cancer Center | New Orleans, Louisiana, United States | Recruiting |
| Christus Highland/ Boniol | Shreveport, Louisiana, United States | Recruiting |
+ 45 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05059444